List of Excipients in Branded Drug AQUASOL A PARENTERAL

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Rising Pharma Holdings Inc	AQUASOL A PARENTERAL	water-miscible retinyl palmitate	64980-721	CHLOROBUTANOL
Rising Pharma Holdings Inc	AQUASOL A PARENTERAL	water-miscible retinyl palmitate	64980-721	CITRIC ACID MONOHYDRATE
Rising Pharma Holdings Inc	AQUASOL A PARENTERAL	water-miscible retinyl palmitate	64980-721	POLYSORBATE 80
Rising Pharma Holdings Inc	AQUASOL A PARENTERAL	water-miscible retinyl palmitate	64980-721	SODIUM HYDROXIDE

AQUASOL A PARENTERAL Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: November 5, 2026

Aquasol A Parenteral is an injectable vitamin A product used when oral administration is impractical or inadequate. Its commercial value is driven by formulation stability, hospital supply reliability, pediatric and nutrition-support demand, and manufacturing control rather than by a strong active-ingredient patent estate. The principal formulation challenge is maintaining vitamin A palmitate in a sterile, injectable, oxidation-resistant dosage form while controlling surfactant exposure and injection-site tolerability.

What is Aquasol A Parenteral?

Aquasol A Parenteral contains vitamin A palmitate, also known as retinyl palmitate, for intramuscular administration. Vitamin A is required for vision, epithelial integrity, immune function, growth, and cellular differentiation. Parenteral treatment is generally reserved for deficiency states in which oral administration is not feasible or absorption is inadequate.[1]

Attribute	Aquasol A Parenteral
Active ingredient	Vitamin A palmitate
Pharmacologic class	Vitamin A replacement
Route	Intramuscular injection
Typical labeled strength	50,000 USP units per mL in historical U.S. labeling
Primary use	Vitamin A deficiency when oral therapy is unsuitable
Dosage form	Sterile injectable solution or dispersion
Commercial buyers	Hospitals, pharmacies, nutrition-support programs, government purchasers
Primary formulation risks	Oxidation, light sensitivity, phase instability, adsorption, injection-site irritation
Patent profile	Mature active ingredient with limited apparent product-specific patent leverage

Vitamin A palmitate is a lipophilic ester. It does not dissolve readily in water, so an injectable formulation requires a solubilization or dispersion system. This distinguishes Aquasol A from ordinary oral vitamin A products.

What excipients are used in Aquasol A Parenteral?

Public labeling for Aquasol A identifies polysorbate 80 as a formulation excipient. Historical product information also associates the formulation with an aqueous parenteral vehicle and antimicrobial protection appropriate to the marketed presentation.[1] Exact excipient composition, concentration, preservative status, and container configuration must be controlled against the current approved labeling for the specific manufacturer and package.

Excipient functions

Excipient function	Strategic objective	Main development risk
Surfactant, such as polysorbate 80	Disperse or solubilize vitamin A palmitate	Peroxide formation, degradation, irritation, particulate generation
Aqueous vehicle	Permit intramuscular delivery	Hydrolysis, microbial risk, osmolality control
Preservative, where used	Support multidose presentation	Toxicity, regulatory restrictions, pediatric acceptability
Antioxidant or chelator	Reduce oxidative degradation	Compatibility and regulatory burden
Tonicity modifier	Improve injection tolerability	Precipitation or formulation instability
Nitrogen headspace	Reduce oxygen exposure	Packaging and filling complexity
Light-protective container	Limit photodegradation	Higher packaging cost and inspection requirements

The central excipient issue is not simply whether vitamin A palmitate can be dispersed. The product must retain potency throughout manufacturing, sterilization, storage, shipping, and administration. Surfactant quality is particularly important because polysorbates can contain or generate peroxides and other reactive species that accelerate oxidation of sensitive compounds.[2]

What is the preferred excipient strategy?

A defensible development strategy has four layers:

1. Minimize surfactant concentration.
   Use the lowest concentration that maintains potency, uniformity, syringeability, and absence of visible or subvisible particles.

2. Control oxidative stress.
   Specify low-peroxide surfactant grades, limit oxygen exposure during compounding and filling, validate nitrogen overlay where justified, and use light-resistant primary packaging.

3. Control interfacial losses.
   Evaluate adsorption to glass, elastomers, filters, tubing, and transfer assemblies. Vitamin A palmitate and surfactant assemblies can behave differently across container surfaces.

4. Match the vehicle to the intended presentation.
   A single-dose preservative-free product may support pediatric and hospital use, while a multidose product may reduce packaging cost but create preservative and microbial-control issues.

How should a new Aquasol A formulation be designed?

A new formulation should begin with a quality-by-design assessment of the critical material attributes of vitamin A palmitate and the critical process parameters governing dispersion and sterile filling.[3]

Recommended formulation-development sequence

Development stage	Key studies
Raw-material screening	Potency, ester composition, impurity profile, peroxide value, particle-size distribution
Surfactant selection	Polysorbate 80 grade comparison, nonionic surfactant alternatives, oxidative compatibility
Vehicle optimization	pH, osmolality, viscosity, preservative level, buffer necessity
Container studies	Type I glass, cyclic olefin polymer, elastomer compatibility, adsorption
Stress testing	Light, oxygen, heat, freeze-thaw, agitation, shipping simulation
Sterile-process assessment	Sterile filtration feasibility, aseptic processing, terminal sterilization compatibility
Product performance	Assay uniformity, resuspendability if dispersed, particulate matter, injection force
Stability program	Accelerated, long-term, in-use, photostability, microbial integrity

Terminal sterilization may be difficult if the vitamin A ester or surfactant system is heat-sensitive. Aseptic processing with sterilized components may therefore be preferable, but it imposes higher process-validation and contamination-control requirements.

What formulation attributes are commercially valuable?

The most valuable improvements are operational rather than cosmetic:

• Preservative-free single-dose ampoules or prefilled syringes.
• Lower injection volume at equivalent dose.
• Reduced injection-site irritation.
• Longer shelf life under controlled room-temperature conditions.
• Better resistance to light and oxygen exposure.
• Lower particulate burden.
• Simplified preparation for pharmacy and nutrition-support staff.
• Ready-to-administer packaging for pediatric and intensive-care settings.

A prefilled syringe could reduce preparation steps and dosing errors. It also increases device, extractables-and-leachables, siliconization, and combination-product requirements.

What patents protect Aquasol A Parenteral?

Aquasol A's active ingredient is a long-established vitamin A ester. The core composition is unlikely to be protected by a live composition-of-matter patent. Commercial protection would more likely come from:

• A narrowly defined surfactant system.
• A specific vitamin A palmitate particle-size distribution.
• A low-oxygen or antioxidant formulation.
• A preservative-free multidose or single-dose configuration.
• A prefilled delivery device.
• A manufacturing process that improves potency or reduces degradation.
• A method of treating a narrowly defined deficiency population.

The U.S. FDA Orange Book is the principal source for identifying patents and regulatory exclusivities associated with approved drug products.[4] Aquasol A is not generally regarded as a modern patent-protected specialty product. A current freedom-to-operate review should focus on formulation and device patents rather than expecting an active-ingredient patent barrier.

How strong is the patent estate for Aquasol A?

Patent category	Likely strength
Vitamin A palmitate composition-of-matter patent	Very weak or expired
Basic injectable vitamin A formulation	Weak unless narrowly differentiated
Polysorbate-based formulation	Weak to moderate; broad claims face prior-art pressure
Specific low-peroxide excipient system	Moderate if supported by unexpected stability data
Prefilled syringe or delivery system	Moderate, depending on device architecture
Manufacturing process	Moderate where process conditions produce measurable quality benefits
Method of use	Limited unless tied to a specific patient population or treatment protocol

The strongest protection would come from a formulation that demonstrates a measurable technical advantage, such as materially improved stability, reduced degradation products, lower injection-site reactions, or a meaningful shelf-life extension.

When does Aquasol A lose exclusivity?

Aquasol A's commercial exclusivity is not primarily determined by a remaining active-ingredient patent term. Vitamin A palmitate is an established ingredient, and competing products can potentially rely on abbreviated or other established regulatory pathways, depending on the product's current regulatory classification and reference-product status.

The practical exclusivity timeline is therefore shaped by:

1. The status of the approved product application.
2. Whether the product is listed as a reference product.
3. Whether any formulation or method-of-use patents are listed.
4. Whether a competing product can demonstrate pharmaceutical equivalence and bioequivalence, where required.
5. Whether the injectable presentation raises additional clinical or quality requirements.

A new entrant should not assume that the absence of a composition patent eliminates regulatory barriers. Injectable products face strict requirements for sterility, particulate control, container closure integrity, extractables and leachables, and manufacturing validation.[5]

What is the Orange Book status of Aquasol A?

The Orange Book identifies approved drug products and, where applicable, patent and exclusivity information.[4] Aquasol A's commercial opportunity should be evaluated against its current listing, application status, and any approved competing vitamin A injections. The product's age and mature ingredient profile suggest limited value from an Orange Book patent-blocking strategy.

For business planning, the more relevant regulatory questions are:

• Is the product currently approved and actively marketed?
• Is there a reference-listed drug suitable for an abbreviated application?
• Is the dosage form listed as a solution, suspension, or other injectable category?
• Does the approved label support the proposed strength and route?
• Are there FDA shortage or discontinuation records affecting supply?
• Is the proposed product a pharmaceutical equivalent or a reformulated product?

A formulation materially different from the reference product may require a more complex regulatory pathway, particularly if it changes excipients, physical state, delivery device, dose uniformity, or clinical performance.

Which companies are challenging Aquasol A?

No major publicly established Paragraph IV litigation campaign is associated with Aquasol A comparable to the litigation surrounding high-value small-molecule products. The competitive field is more likely to include:

• Vitamin manufacturers supplying hospital products.
• Compounding pharmacies.
• Nutrition-support suppliers.
• Multivitamin injectable manufacturers.
• International vitamin A injection producers.
• Contract manufacturers with sterile-fill capacity.

Paragraph IV risk depends on the presence of listed patents and the legal basis of the competing application. For a mature vitamin injectable, the principal competitive threat may be commercial launch after regulatory approval rather than patent litigation.

What generic entry risks exist for Aquasol A?

Generic entry risk is high at the ingredient level but moderate at the finished-product level. The active ingredient is inexpensive and widely available, but sterile injectable manufacturing is capital-intensive.

Generic-entry advantages

• Established pharmacology.
• Low-cost vitamin A palmitate raw material.
• Limited apparent composition-patent protection.
• Familiar excipient classes.
• Potentially simple clinical positioning.

Generic-entry barriers

• Sterile manufacturing capacity.
• Oxidation control.
• Consistent dispersion or solubilization.
• Low particulate levels.
• Container closure integrity.
• Stability under light and temperature stress.
• Limited commercial volume.
• Hospital procurement qualification.
• Regulatory scrutiny of excipient changes.

The result is a product with relatively low intellectual-property barriers but meaningful quality and supply-chain barriers. This profile can deter entrants even when patent risk is minimal.

What commercial opportunities exist for Aquasol A excipients?

The highest-value opportunities are likely to come from reformulation and supply reliability.

1. Preservative-free single-dose presentation

A preservative-free ampoule or prefilled syringe could target neonatal, pediatric, intensive-care, and pharmacy-prepared use. The tradeoff is higher unit cost and greater packaging demand. A single-dose product must maintain sterility through the full labeled storage period without relying on antimicrobial preservatives.

2. Improved oxidative stability

A low-peroxide polysorbate system, oxygen-reduced filling process, and light-protective container could support a longer shelf life or fewer storage restrictions. Any commercial claim must be supported by comparative stability data and degradation-product analysis.

3. Ready-to-administer hospital product

Hospitals may value a standardized, ready-to-use injection more than a lower-cost vial. Commercial differentiation could include:

• Unit-dose labeling.
• Barcode-ready packaging.
• Reduced preparation time.
• Smaller injection volume.
• Tamper-evident packaging.
• Compatibility with automated medication systems.

4. Global-market formulation platform

Vitamin A deficiency remains a public-health concern in selected regions, while injectable use is concentrated in patients who cannot absorb or receive oral therapy.[6] A platform could use the same stabilized formulation in multiple strengths or package sizes, subject to regional regulatory requirements.

5. Contract development and manufacturing

A manufacturer with sterile-fill capability could offer Aquasol A-equivalent products to regional pharmaceutical companies. The value proposition would be formulation transfer, analytical methods, aseptic filling, and regulatory documentation rather than ownership of a strong patent estate.

How does Aquasol A compare with oral vitamin A products?

Factor	Aquasol A Parenteral	Oral vitamin A
Patient population	Patients unable to use or absorb oral therapy	Most patients requiring supplementation or treatment
Manufacturing complexity	High due to sterility and injection quality	Lower
Distribution cost	Higher	Lower
Formulation challenge	Lipophilic active in sterile injectable vehicle	Solubilization, capsule, tablet, or liquid formulation
Market volume	Narrower	Broader
Safety management	Higher administration risk	Dose-related toxicity remains important
Commercial differentiation	Stability, packaging, availability	Dose, delivery format, absorption, adherence

Parenteral vitamin A is a niche product. It should not be evaluated against mass-market oral supplements on volume alone. Its value depends on clinical necessity, institutional procurement, and the availability of an approved injectable alternative.

What FDA regulatory issues affect an Aquasol A successor?

FDA review will focus on product quality and equivalence. Relevant areas include:

• Sterility assurance.
• Endotoxin control.
• Particulate matter.
• Assay and degradation products.
• Uniformity of dose.
• Container closure integrity.
• Extractables and leachables.
• Photostability.
• Compatibility with administration equipment.
• Preservative effectiveness, if multidose.
• Stability after opening or dilution, if applicable.

FDA guidance for injectable products emphasizes control of visible and subvisible particles, container closure systems, and manufacturing processes.[5] ICH quality guidelines also support systematic identification of critical quality attributes and process risks.[3]

What manufacturing and IP barriers matter most?

Manufacturing is the principal defensible barrier. A company can create commercial separation through:

• Proprietary premix or dispersion technology.
• Controlled oxygen and light exposure.
• Validated low-shear transfer process.
• Improved sterile filtration strategy.
• Reduced adsorption to manufacturing components.
• Specialized container closure selection.
• Validated prefilled delivery device.
• Stability-indicating analytical package.

A patent filing should focus on measurable technical outcomes. Generic claims covering vitamin A, water, and a surfactant would face substantial prior-art exposure. Narrower claims tied to defined peroxide limits, degradation thresholds, concentration ranges, container materials, or process conditions are more defensible.

What revenue exposure and launch scenarios should investors consider?

Aquasol A is unlikely to support blockbuster revenue. The commercial case depends on supply continuity, procurement contracts, and scarcity value.

Launch scenario	Commercial outcome
Commodity generic vial	Low margin, price competition, limited differentiation
Reliable hospital supply product	Moderate value through contract retention and shortage substitution
Preservative-free unit dose	Higher price per dose, narrower but defensible market
Prefilled syringe	Higher manufacturing cost, stronger workflow differentiation
Global public-health supply	Large unit potential in selected markets, lower pricing and tender pressure
Proprietary stabilized formulation	Moderate premium if shelf-life and quality benefits are demonstrated

A shortage or discontinuation event could increase near-term demand, but shortage-driven revenue is difficult to sustain without manufacturing reliability. The strongest commercial strategy is a quality-led hospital product with dependable supply and a differentiated package configuration.

Key Takeaways

• Aquasol A Parenteral is an injectable vitamin A palmitate product for patients who cannot use oral therapy effectively.
• Its core commercial challenge is formulation stability, not active-ingredient discovery.
• Polysorbate-based solubilization or dispersion requires tight control of peroxide levels, oxygen exposure, light, and container interactions.
• The active ingredient is mature, and the apparent patent position is weak compared with modern specialty pharmaceuticals.
• Generic entry is legally plausible but operationally constrained by sterile manufacturing and quality requirements.
• The strongest opportunities are preservative-free unit doses, prefilled syringes, improved oxidative stability, ready-to-administer packaging, and reliable hospital supply.
• A defensible patent strategy should target specific excipient systems, manufacturing conditions, container configurations, or demonstrated stability advantages.
• Revenue expectations should be based on niche institutional demand, tender access, and supply reliability rather than mass-market vitamin sales.

FAQs

Is Aquasol A Parenteral a biologic?

No. Aquasol A is a small-molecule vitamin product containing vitamin A palmitate. Biosimilar regulation does not apply.

Can vitamin A palmitate be formulated without polysorbate 80?

Potentially, but removing polysorbate 80 requires an alternative solubilization or dispersion system and new studies for potency, particle control, injection tolerability, sterility, and stability.

Is Aquasol A suitable for intravenous administration?

The product is associated with intramuscular administration. Intravenous use should not be assumed unless expressly supported by the applicable approved labeling.

Does a new vitamin A injection need a new clinical trial?

The requirement depends on the regulatory pathway, reference-product relationship, formulation differences, route, strength, and evidence needed to establish equivalence. A materially different formulation may require more than comparative pharmaceutical-quality data.

What is the best patent angle for a new injectable vitamin A product?

The strongest potential claims are likely to cover a defined stabilized excipient system, a low-oxygen manufacturing process, a container closure combination, or a delivery device that produces measurable improvements in stability, usability, or safety.

References

1. U.S. National Library of Medicine. (n.d.). Aquasol A: Vitamin A palmitate injection, solution. DailyMed. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (2016). FDA briefing document: Joint meeting of the Drug Safety and Risk Management Advisory Committee and the Nonprescription Drugs Advisory Committee: Polyethylene glycol 3350. FDA. https://www.fda.gov/

3. International Council for Harmonisation. (2009). ICH Q8(R2): Pharmaceutical development. https://www.ich.org/

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. FDA. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

5. U.S. Food and Drug Administration. (2008). Guidance for industry: Container closure systems for packaging human drugs and biologics. FDA. https://www.fda.gov/

6. World Health Organization. (2009). Global prevalence of vitamin A deficiency in populations at risk 1995-2005: WHO global database on vitamin A deficiency. World Health Organization. https://www.who.int/publications/i/item/9789241598019